We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Akers Bio | LSE:AKR | London | Ordinary Share | COM SHS NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 57.50 | 50.00 | 65.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
19/12/2016 17:09 | I'm not tempted to invest again in Akers. They are a cautionary tale for inexperienced investors. | werewolfie | |
19/12/2016 16:29 | werewolfie That's why they never sold; why would a health enthusiast need a breathalyser? AKR would have made more money selling sticks of chalk and a ruler | norbus | |
19/12/2016 16:16 | WereWolfie - have you seen the breathalysers being used? Fiddly, and a nonsense in the hands of a drunk or someone with a hangover. But in the hands of a health enthusiast, potentially quite different. Mcm - Ray Akers may or may not have said things in bad faith, but it is interesting to note that he does not feature anywhere in today's release. This news belongs to Gormally. | wigwammer | |
19/12/2016 16:05 | mcm They should make disposable lie detector tests and try them on Walter When Walter lies, they have to dispose of him. They had phenomenally lucrative news Never once did any come off | norbus | |
19/12/2016 16:02 | I thought selling breath tests to the French 4 years ago was a magnificent situation but here we are - still a penny share | werewolfie | |
19/12/2016 11:46 | HIT is a significant issue for hospitals, but not one of the most significant. The potential savings are meaningful - perhaps running into seven figures - but not running into tens of millions. It doesn't take a great leap of imagination to believe therefore, that it has taken a more senior level of marketing presence to raise awareness of platelet factor 4 up the echelons of the decision structure. So while this does not represent a multi billion dollar stocking order, the fact that it is being trialled in a large and prestigious hospital group is, I suggest, a significant step in the right direction. | wigwammer | |
19/12/2016 10:57 | You need to ask, why had they not tried it before? its been around yonks. Why announce a trial ? a promise but not a delivery; I think It smells; No it stinks | norbus | |
19/12/2016 07:13 | Looks like a potentially lucrative agreement with a group of up to 300 New York hospitals to introduce the PIFA tests: "John J. Gormally, Chief Executive Officer of Akers Bio, commented: "Akers Bio is delighted to have signed a three-year agreement with GNYHA, one of the premier group purchasing organizations in the United States healthcare sector. Their membership includes a diverse listing of prominent and large integrated delivery networks (IDNs) and hospitals. Enhanced access to GNYHA's network has the potential to dramatically increase domestic sales of our flagship product." | rivaldo | |
16/12/2016 15:52 | Post 3335 has nothing to do with AKR.But it's still there. | wigwammer | |
16/12/2016 11:00 | Lol. I could prove it, but the CAP board has disappeared.I can't think why... | wigwammer | |
16/12/2016 10:06 | "Thomas must be laughing he got away. I am."Yes, but you put the proceeds into CAP. | wigwammer | |
16/12/2016 09:17 | mcm That's it; Gormally not executing along his track record. mirrors Walter; Suspect Gormally burned out and on his knees when caught by Walter. Thomas must be laughing he got away. I am.* Expected more sobriaty id there was terra firma under the story | norbus | |
16/12/2016 08:49 | Worryingly Norbus it raises slight concerns whether Gormally might actually be cut from the same cloth as Walter. Haven't seen anything re concrete numbers and not sure whether this was definitely notifiable to the market, but it has done far more harm than good for the share price | mcmather | |
14/12/2016 09:14 | mcm Pleased with the share price bump 2/12/2016; anyone checked the steps to real full on sales? Major Major Win, Very very very Many many many good news to follow | norbus | |
13/12/2016 18:43 | To be taken seriously, akr needs to keep wally away from the front line: One thing of possible interest though is that this will apparently be the first of AKR products that will be marketed under the "First Check" brand. Apparently "First Check" simply pay AKR then market / price the product themselves under their brand name. Could be interesting going forward. | mcmather | |
05/12/2016 09:17 | "Noddy" = puerileRamridge - if you want to respond to post 3326 then please feel free. Otherwise, best wishes with your investments. | wigwammer | |
04/12/2016 15:02 | Well done. You corrected the spelling.Its a start. | wigwammer | |
04/12/2016 09:18 | "Npddy" You certainly missed something | wigwammer | |
04/12/2016 06:46 | Noddy You still miss the point | norbus | |
02/12/2016 13:48 | Ramridge - one is a monitoring device, the other is a disposable test. Management clearly believe the product has a unique place and potential, and Alere (a multi billion usd multinational) appears to agree with them. "A nod is as good as a wink to a blind horse.." I nodded at 90p, ta ta now. | wigwammer |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions